HER2-low breast cancer could be associated with an increased risk of brain metastasis-Reference-Cited by-同舟云学术

HER2-low breast cancer could be associated with an increased risk of brain metastasis

Published:2021-10-18 Issue:2 Volume:27 Page:332-339
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Guven Deniz Can^ORCID,Kaya Mehmet Burak,Fedai Burak,Ozden Mucahit,Yildirim Hasan Cagri,Kosemehmetoglu Kemal,Kertmen Neyran,Dizdar Omer,Uner Aysegul,Aksoy Sercan

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-021-02049-w.pdf

Reference39 articles.

1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

2. Szymiczek A, Lone A, Akbari MR (2021) Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review. Clin Genet 99:613–637

3. van Maaren MC, de Munck L, Strobbe LJA et al (2019) Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer 144:263–272

4. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277

5. Rouanet P, Roger P, Rousseau E et al (2014) HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med 3:134–142

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of HER2-low status on brain metastasis-free survival and survival after brain metastasis in patients with breast cancer;Clinical and Translational Oncology;2024-08-10

2. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort;ESMO Open;2024-05

3. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer;ESMO Open;2024-04

4. Human Epidermal Growth Factor Receptor 2–Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population;JCO Precision Oncology;2024-03

5. New insights into HER2-low breast cancer brain metastasis: A retrospective analysis;The Breast;2024-02